Skip to main content

Table 2 Patient characteristics and characterization of cell products

From: Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

 

Patient number

 

1

2

3

4

5

6

7

8

9

10

Sex (M/F)

F

F

F

M

M

M

F

M

M

M

Age (years)

37

42

49

42

44

41

30

32

64

54

BMI (kg/m2)

27.9

22.6

26.5

22.2

20.3

38

20.2

26.7

23.1

23.5

Hypertension (yes/no)

N

N

Y

N

N

Y

N

N

N

N

Diabetes mellitus (yes/no)

N

N

N

N

N

N

N

N

N

N

Smoking history (yes/no)

N

N

N

N

N

Y

N

N

Y

N

Duration of LBP (months)

96

12

14

29

7

37

96

72

36

84

Implanted disc level

L4/5

L4/5

L4/5

L4/5

L4/5

L4/5, L5/S1

L4/5

L4/5

L4/5

L4/5

Preoperative VAS

8

7

6

7

4

7

6

6

6

7

Preoperative ODI

40

34

30

50

32

72

54

32

32

60

Preoperative Pfirrmann’s grade

IV

IV

IV

IV

IV

IV

IV

IV

IV

IV

Cell number (× 107/vial)

4.7

5.3

5.4

5.3

5.4

5.0

5.3

5.0

5.2

4.7

Cell viability (%)

93.62

91.55

97.57

88.30

97.09

89.44

87.13

94.38

94.55

89.93

Cell surface marker

CD44 (%)

94.50

84.80

98.00

99.90

99.90

100

99.8

99.9

98.3

99.2

CD73 (%)

98.40

98.60

99.90

100.00

99.60

100

100

100

99.9

99.9

CD45 (%)

1.00

0.81

0.20

0.48

0.51

0.75

0.19

0.49

0.7

0.67

CD29 (%)

90.80

97.50

99.80

99.90

99.90

100.00

100.00

100.00

100.00

99.90

TGF-β receptor III

98.20

99.10

99.60

100.00

99.70

99.10

99.90

100.00

99.40

99.80

  1. M male, F female, BMI body mass index, LBP low back pain, VAS visual analogue scale, ODI Oswestry Disability Index, TGF-β transforming growth factor beta